JP2022550037A - 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン - Google Patents

局所進行性扁平上皮癌を有する患者の治療のための投与レジメン Download PDF

Info

Publication number
JP2022550037A
JP2022550037A JP2022518772A JP2022518772A JP2022550037A JP 2022550037 A JP2022550037 A JP 2022550037A JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022550037 A JP2022550037 A JP 2022550037A
Authority
JP
Japan
Prior art keywords
administered
compound
pharmaceutically acceptable
acceptable salt
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550037A5 (cg-RX-API-DMAC7.html
Inventor
ブリエンツァ,シルヴァーノ
ザーナ,クラウディオ
アルトマン,セルジオ エイドリアン シルダーゲマジン
ボウリス,ジーン
Original Assignee
デバイオファーム インターナショナル エス.エー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デバイオファーム インターナショナル エス.エー. filed Critical デバイオファーム インターナショナル エス.エー.
Publication of JP2022550037A publication Critical patent/JP2022550037A/ja
Publication of JP2022550037A5 publication Critical patent/JP2022550037A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022518772A 2019-09-25 2020-09-25 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン Pending JP2022550037A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962905703P 2019-09-25 2019-09-25
US62/905,703 2019-09-25
US202063016762P 2020-04-28 2020-04-28
US63/016,762 2020-04-28
EP20184601 2020-07-07
EP20184601.1 2020-07-07
PCT/EP2020/076994 WO2021058794A1 (en) 2019-09-25 2020-09-25 Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Publications (2)

Publication Number Publication Date
JP2022550037A true JP2022550037A (ja) 2022-11-30
JP2022550037A5 JP2022550037A5 (cg-RX-API-DMAC7.html) 2023-10-02

Family

ID=72644266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518772A Pending JP2022550037A (ja) 2019-09-25 2020-09-25 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン

Country Status (13)

Country Link
US (1) US20250268863A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034102A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022550037A (cg-RX-API-DMAC7.html)
KR (1) KR20220088700A (cg-RX-API-DMAC7.html)
CN (1) CN114727984A (cg-RX-API-DMAC7.html)
AU (1) AU2020356356A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005624A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022004947A2 (cg-RX-API-DMAC7.html)
IL (1) IL291682A (cg-RX-API-DMAC7.html)
MX (1) MX2022003628A (cg-RX-API-DMAC7.html)
PH (1) PH12022550721A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021058794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022275A1 (zh) * 2022-07-29 2024-02-01 苏州科睿思制药有限公司 Xevinapant的晶型及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525585T3 (es) 2006-05-05 2014-12-26 The Regents Of The University Of Michigan Intermedios para la preparación de miméticos de SMAC bivalentes
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
ES2643233T3 (es) 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
EP2493879B1 (en) 2009-10-28 2014-05-14 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant))
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
AR101479A1 (es) 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
AU2015360095B2 (en) * 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
CA2916970A1 (en) 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
EP3419643A4 (en) 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. SMC COMBINATION THERAPY FOR TREATING CANCER
CN110475567A (zh) 2017-03-31 2019-11-19 勃林格殷格翰国际有限公司 抗癌组合疗法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE LE TOURNEAU, ET AL.: "A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in", MEETING ABSTRACT, 2014 ASCO ANNUAL MEETING, JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.32, No.15_suppl, JPN6024034251, 20 May 2014 (2014-05-20), ISSN: 0005536693 *
RADIOTHERAPY AND ONCOLOGY, vol. 119, no. 1, JPN6024034252, 2016, pages 245 - 246, ISSN: 0005536694 *

Also Published As

Publication number Publication date
US20250268863A1 (en) 2025-08-28
PH12022550721A1 (en) 2024-05-13
AU2020356356A1 (en) 2022-05-12
IL291682A (en) 2022-05-01
MX2022003628A (es) 2022-07-21
CA3151770A1 (en) 2021-04-01
CO2022004947A2 (es) 2022-08-30
EP4034102A1 (en) 2022-08-03
CN114727984A (zh) 2022-07-08
KR20220088700A (ko) 2022-06-28
WO2021058794A1 (en) 2021-04-01
BR112022005624A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP7579465B2 (ja) 頭頸部癌の治療のためのegfr阻害剤
CN103533961B (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
JP7332293B2 (ja) バルリチニブおよび抗癌剤を含んでなる併用療法
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
JP2019530752A (ja) がんを治療するための薬物の調製における、抗pd‐1抗体とvegfr阻害剤とを組み合わせた使用
JP2016523858A (ja) がんを治療するためのbtk阻害剤とフルオロウラシルとの併用
JP2021054832A (ja) 薬学的組み合わせ
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CN103533940A (zh) 治疗晚期实体瘤的方法
WO2015185011A1 (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
TW202535477A (zh) 抗b7h3抗體—藥物偶聯物治療癌症的方法
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
US12611403B2 (en) Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody
CN113194941A (zh) 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌
JP2025509278A (ja) 小細胞肺癌を治療する方法
US20250268863A1 (en) Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
US20190276439A1 (en) Method of treating solid tumors
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
CN113573707A (zh) 用于治疗癌症的组合产品
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
HK40122430A (en) Method for treating cancer with anti-b7h3 antibody-drug conjugate
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250226